Kyntra Bio, Inc. (KYNB)
6.27
+0.31
(+5.20%)
USD |
NASDAQ |
Oct 09, 14:24
Kyntra Bio EPS Diluted (Quarterly) : 2.958 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.958 |
| March 31, 2026 | -3.755 |
| December 31, 2025 | -3.611 |
| September 30, 2025 | 36.71 |
| June 30, 2025 | -1.881 |
| March 31, 2025 | 0.046 |
| December 31, 2024 | 4.458 |
| September 30, 2024 | -4.249 |
| June 30, 2024 | -3.893 |
| March 31, 2024 | -8.318 |
| December 31, 2023 | -14.27 |
| September 30, 2023 | -0.6475 |
| June 30, 2023 | -0.8972 |
| March 31, 2023 | -0.8101 |
| December 31, 2022 | -0.7038 |
| September 30, 2022 | -0.9774 |
| June 30, 2022 | -0.7769 |
| March 31, 2022 | -0.6793 |
| December 31, 2021 | -1.445 |
| September 30, 2021 | 0.5366 |
| June 30, 2021 | -1.452 |
| March 31, 2021 | -0.7826 |
| December 31, 2020 | -16.08 |
| September 30, 2020 | 0.3523 |
| June 30, 2020 | -0.9537 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.8881 |
| December 31, 2019 | -1.123 |
| September 30, 2019 | -0.5682 |
| June 30, 2019 | 1.265 |
| March 31, 2019 | -0.5299 |
| December 31, 2018 | 0.2296 |
| September 30, 2018 | -0.5036 |
| June 30, 2018 | -0.2796 |
| March 31, 2018 | -0.4996 |
| December 31, 2017 | -10.31 |
| September 30, 2017 | -8.057 |
| June 30, 2017 | -11.46 |
| March 31, 2017 | -11.95 |
| December 31, 2016 | -0.5341 |
| September 30, 2016 | -0.38 |
| June 30, 2016 | 0.35 |
| March 31, 2016 | -0.45 |
| December 31, 2015 | -0.83 |
| September 30, 2015 | -0.74 |
| June 30, 2015 | 0.83 |
| March 31, 2015 | -0.78 |
| December 31, 2014 | -1.45 |
| September 30, 2014 | -1.428 |
| June 30, 2014 | 0.4599 |
| March 31, 2014 | -0.2862 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Vericel Corp. | 0.0422 |
| Nektar Therapeutics | -1.229 |
| Capricor Therapeutics, Inc. | -0.7032 |
| ARS Pharmaceuticals, Inc. | -0.6277 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 11.97M |
| Revenue (Quarterly) | -1.474M |
| Total Expenses (Quarterly) | -13.45M |
| Enterprise Value | -45.19M |
| Profit Margin (Quarterly) | -812.3% |
| Earnings Yield | 515.2% |
| Normalized Earnings Yield | 533.61 |